0 products, total $0.+86-400-890-9989      Login |  Register 中文한국어

Browse By Molecule:

Your Position: Home > Recombinant Protein > CHO Cell Expressed > Interferon beta / IFN-beta / IFNB Protein (Native)

Interferon beta / IFN-beta / IFNB Protein (Native) PDF Download

Catalog Size (Price) Quantity In Stock Operation Other Information
10704-HNAC
  YES          

Interferon beta / IFN-beta / IFNB Protein

 

IFN-beta / IFNB Protein Price Inquiry ( Available Sizes )

IFN-beta / IFNB Protein Product Information

Synonym :

IFNB1,  IFB,  IFF,  IFNB,  MGC96956

Protein Construction:

A DNA sequence encoding the human IFNβ ( NP_002167.1 ) ( Met 1 - Asn 187 ) was expressed and purified

Source: Human
Expression Host: CHO stable cells

IFN-beta / IFNB Protein QC Testing

Purity: > 92 % as determined by SDS-PAGE SDS-PAGE:
IFNB protein

IFNB protein

Bio-activity:

Measured in antiviral assays using WISH human amnion cells infected with vesicular stomatitis virus (VSV)
The EC50 for this effect is typically 10 - 50 pg/mL
Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method
Stability: Samples are stable for up to twelve months from date of receipt at -70℃
Predicted N terminal: Met 22
Molecular Mass:

The recombinant human IFNβ consists of 166 amino acids and has a predicted molecular mass of 20 kDa. In SDS-PAGE under reducing conditions, the apparent molecular mass of rh IFNβis approximately 22 -24 kDa.

Formulation: Lyophilized from sterile 20mM  HEPES, 150mM NaCl, pH 7.2
  1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
  2. Please contact us for any concerns or special requirements.

IFN-beta / IFNB Protein Usage Guide

Storage: Store it under sterile conditions at -70℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution: A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

IFN-beta / IFNB Protein Related Products & Topics

Related Areas:

Cancer>>Angiogenesis>>Cytokines/Chemokines in Angiogenesis>>IFN beta/IFNB

Immunology>>Cytokine & Receptor>>Interleukin & Receptor >>IL-10/Interferon Family>>IFN beta/IFNB

Proteins:

Molecule Species Description //For Detailed Info. and Price------CLICK! Cat. No
IFN beta/IFNB Human IFN beta/IFNB/Fc Protein, Recombinant 10704-H02H
IFN beta/IFNB Human IFN beta/IFNB Protein, Recombinant 10704-HNAC

Antibodies:

Molecule Application Description //For Detailed Info. and Price------CLICK! Cat. No
Human
IFN beta/IFNB
WB, ELISA Mouse Monoclonal Antibody 10704-MM01

IFN-beta / IFNB Protein Description

Interferons (IFNs) are natural glycoproteins belonging to the cytokine superfamily, and are produced by the cells of the immune system of most vertebrates in response to challenges by foreign agents such as viruses, parasites and tumor cells. IFNs are produced by a wide variety of cells in response to the presence of dsRNA, a key indicator of viral infection via a pattern recognition receptor of the innate immune system Toll Like Receptor 3 (TLR 3), and in turn assists the immune response by inhibiting viral replication within host cells, activating natural killer cells and macrophages, increasing antigen presentation to lymphocytes, and inducing the resistance of host cells to viral infection. There are three major classes of IFNs according to the receptor type through which they signal, and the type I IFNs bind to a specific receptor complex known as the IFN-α receptor (IFNAR) consisting of IFNAR1 and IFNAR2 chains. The type I  IFNs present in humans are IFN-α, IFN-β and IFN-ω and IFN-β is produced by fibroblast. In addition to the common antiviral activity, IFN-β also induces increased production of the p53 gene product which promotes apoptosis, and thus has therapeutic effect against certain cancers. Furthermore, IFN-β might play a beneficial role in the development of a chronic progressive CNS inflammation.

References

  1. Morikawa K. et al., 1987, J Immunol. 139: 761-6.
  2. Sato K. et al., 2001, Eur J Immunol. 31: 3188-46.
  3. Takaoka A. et al., 2003, Nature. 424: 516-23.
  4. Improta T. et al., 1997, Cytokine. 9: 383-93.
  5. Teige I. et al., 2006, J Immunol. 177: 3542-53.
 

 

IFN beta related areas, pathways, and other information